Jupiter Neurosciences wins exclusive U.S. rights to ALA-002

Jupiter Neurosciences said Tuesday it signed a definitive license agreement for perpetual exclusive U.S. rights to ALA-002, a patented MDMA-based candidate with FDA Novel Chemical Entity designation. The deal could be worth up to $100 million and gives the company a second clinical-stage CNS program alongside its Parkinson’s drug, JOTROL™.

Why it matters: - The agreement turns Jupiter Neurosciences from a single-program CNS developer into a two-asset clinical-stage company. - The deal adds a patented psychedelic medicine candidate with FDA Novel Chemical Entity status, which can provide five years of data exclusivity after approval. - The transaction gives Jupiter a U.S. commercial path in a psychedelic therapeutics market the company says is expanding quickly.

What happened: - Jupiter Neurosciences entered a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002. - The company said the transaction has a potential value of up to $100 million, including milestone payments and excluding ongoing royalties. - Jupiter said the agreement broadens its pipeline beyond JOTROL™, its enhanced-bioavailability resveratrol program now in a Phase IIa Parkinson’s disease trial. - The company described ALA-002 as a patented, non-racemic MDMA formulation designed to improve cardiovascular safety and reduce abuse liability while preserving therapeutic effects.

The details: - Jupiter will pay $3.3 million upfront, including $1.5 million in cash and $1.8 million in JUNS common stock subject to a 120-day lock-up. - Jupiter will owe $3.3 million when the program reaches Phase 3 first patient in. - Jupiter will owe $20 million upon U.S. NDA approval. - Commercial milestones are set at $10 million, $30 million and $33.3 million when cumulative U.S. net sales reach $333 million, $1 billion and $2 billion. - Jupiter will pay a 3% royalty on net sales after the third commercialization milestone. - The agreement grants perpetual, exclusive U.S. rights to ALA-002. - PharmAla will continue manufacturing ALA-002 drug product for Jupiter under commercial terms to be negotiated. - PharmAla said its MDMA supply is already active in U.S. government-sponsored VA and DHA clinical trials. - Jupiter said the asset targets a U.S. psychedelic therapeutics market estimated at $3 billion in 2024 and $8 billion by 2030, citing Strategic Market Research. - Jupiter said ALA-002 is being developed for patients with treatment-resistant PTSD, anxiety and related neuropsychiatric conditions.

Between the lines: - The deal appears designed to reduce Jupiter’s dependence on a single clinical asset while giving the company exposure to a separate CNS and psychedelic medicine opportunity. - The stock-and-cash structure preserves cash while still giving PharmAla upside if development advances. - Jupiter linked the transaction to the April 18, 2026 executive order on investigational psychedelic therapies, which could create a more favorable regulatory backdrop, but that remains subject to future FDA, DEA and clinical decisions. - Management said the company has also been building out its psychedelic medicines strategy, including adding Drs. Tomas Philipson and Andrew Cutler to the board.

What's next: - Jupiter said the next priorities are clinical execution, capital allocation and advancement of both programs toward milestone events. - PharmAla will continue developing ALA-002 outside the United States. - Jupiter said the next 12 months will be transformative for the company. - The agreement still faces the usual risks tied to clinical development, regulatory review, financing and closing conditions.

The bottom line: - Jupiter is betting that exclusive U.S. rights to ALA-002 can deepen its CNS pipeline and create a second value driver while Parkinson’s drug development continues.